Increased Restenosis Rate After Implantation of Drug-Eluting Stents in Patients With Elevated Serum Activity of Matrix Metalloproteinase-2 and -9

JACC: Cardiovascular Interventions

Volumn 3, Issue 1, 2010, Pages 90-97

  Katsaros, Katharina M ^a   Kastl, Stefan P ^a   Zorn, Gerlinde ^a   Maurer, Gerald ^a   Wojta, Johann ^a   Huber, Kurt ^b   Christ, Günter ^a   Speidl, Walter S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

angioplasty; drug eluting stents; metalloproteinases; restenosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; LOGISTIC MODELS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; ODDS RATIO; PACLITAXEL; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 74049128034     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.10.023     Document Type: Article

References (26)

1. Cosgrave J., Melzi G., Corbett S., et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 49 (2007) 2320-2328
2. Virmani R., and Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 10 (1999) 499-506
3. Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., and Reidy M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75 (1994) 539-545
4. George S.J., Zaltsman A.B., and Newby A.C. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res 33 (1997) 447-459
5. James T.W., Wagner R., White L.A., Zwolak R.M., and Brinckerhoff C.E. Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle-derived cell line. J Cell Physiol 157 (1993) 426-437
6. Southgate K.M., Fisher M., Banning A.P., et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res 79 (1996) 1177-1187
7. Cedro K., Radomski A., Radomski M.W., Ruzyllo W., and Herbaczynska-Cedro K. Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study. Int J Cardiol 92 (2003) 177-180
8. Mason D.P., Kenagy R.D., Hasenstab D., et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res 85 (1999) 1179-1185
9. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
10. Zemlianskaia O.A., Panchenko E.P., Samko A.N., et al. [Matrix metalloproteinases, C-reactive protein, and markers of thrombinemia in patients with stable angina and restenoses after percutaneous coronary interventions.]. Kardiologiia 44 (2004) 4-12
11. Ge J., Shen C., Liang C., Chen L., Qian J., and Chen H. Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. Int J Cardiol 112 (2006) 85-90
12. Jones G.T., Kay I.P., Chu J.W., et al. Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 26 (2006) e121-e125
13. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., and Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 (1996) 2277-2283
14. Wiskirchen J., Schober W., Schart N., et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol 39 (2004) 565-571
15. Dupont W.D., and Plummer Jr. W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 11 (1990) 116-128
16. Marx S.O., Jayaraman T., Go L.O., and Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
17. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
18. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
19. Li C., Cantor W.J., Nili N., et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 39 (2002) 1852-1858
20. Galis Z.S., Johnson C., Godin D., et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91 (2002) 852-859
21. Dollery C.M., Humphries S.E., McClelland A., Latchman D.S., and McEwan J.R. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 99 (1999) 3199-3205
22. Bendeck M.P., Conte M., Zhang M., Nili N., Strauss B.H., and Farwell S.M. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 160 (2002) 1089-1095
23. Bendeck M.P., Irvin C., and Reidy M.A. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 78 (1996) 38-43
24. Zempo N., Koyama N., Kenagy R.D., Lea H.J., and Clowes A.W. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 16 (1996) 28-33
25. Nakayama Y., and Masuda T. Development of a polymeric matrix metalloproteinase inhibitor as a bioactive stent coating material for prevention of restenosis. J Biomed Mater Res B Appl Biomater 80 (2007) 260-267
26. Amorino G.P., and Hoover R.L. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol 152 (1998) 199-207